Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) updated its FY17 earnings guidance on Tuesday. The company provided EPS guidance of $10.70-11.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $11.02. The company issued revenue guidance of $1.625-1.7 billion, compared to the consensus revenue estimate of $1.66 billion.

Several research firms have weighed in on JAZZ. Zacks Investment Research upgraded Jazz Pharmaceuticals PLC from a hold rating to a buy rating and set a $174.00 price target on the stock in a report on Tuesday. BidaskClub lowered Jazz Pharmaceuticals PLC from a hold rating to a sell rating in a report on Thursday, August 3rd. BMO Capital Markets boosted their price target on Jazz Pharmaceuticals PLC from $192.00 to $196.00 and gave the company an outperform rating in a report on Wednesday, June 7th. Janney Montgomery Scott boosted their price target on Jazz Pharmaceuticals PLC from $138.00 to $175.00 and gave the company a buy rating in a report on Tuesday, July 4th. Finally, Leerink Swann boosted their price target on Jazz Pharmaceuticals PLC from $169.00 to $170.00 and gave the company a buy rating in a report on Tuesday, July 4th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eighteen have issued a buy rating to the company. The stock currently has an average rating of Buy and a consensus price target of $182.56.

Shares of Jazz Pharmaceuticals PLC (NASDAQ JAZZ) traded down 2.10% during midday trading on Tuesday, reaching $152.29. The company had a trading volume of 571,951 shares. The company has a 50 day moving average price of $155.76 and a 200-day moving average price of $145.81. The firm has a market capitalization of $9.14 billion, a P/E ratio of 23.01 and a beta of 1.10. Jazz Pharmaceuticals PLC has a one year low of $95.80 and a one year high of $163.75.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $2.56 EPS for the quarter, missing the consensus estimate of $2.75 by $0.19. Jazz Pharmaceuticals PLC had a net margin of 26.28% and a return on equity of 24.65%. The business had revenue of $394.39 million during the quarter, compared to the consensus estimate of $410.83 million. During the same quarter in the prior year, the firm posted $2.67 EPS. The company’s revenue for the quarter was up 3.5% compared to the same quarter last year. On average, analysts anticipate that Jazz Pharmaceuticals PLC will post $11.02 EPS for the current fiscal year.

In other Jazz Pharmaceuticals PLC news, EVP Suzanne Sawochka Hooper sold 420 shares of the business’s stock in a transaction that occurred on Friday, June 23rd. The shares were sold at an average price of $160.00, for a total transaction of $67,200.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Bruce C. Cozadd sold 30,000 shares of the business’s stock in a transaction that occurred on Thursday, May 11th. The stock was sold at an average price of $153.47, for a total transaction of $4,604,100.00. Following the sale, the chief executive officer now directly owns 296,418 shares in the company, valued at approximately $45,491,270.46. The disclosure for this sale can be found here. In the last ninety days, insiders sold 40,600 shares of company stock worth $6,245,820. Insiders own 4.30% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Issues FY17 Earnings Guidance” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/08/08/jazz-pharmaceuticals-plc-nasdaqjazz-issues-fy17-earnings-guidance.html.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Earnings History and Estimates for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.